Drugs / GW117
GW117
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06964711 | Jul 2021 → Mar 2023 | major depressive disorder | Beijing Greatway Pharmaceutical Technology Co.,Ltd. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06796868 | Jul 2022 → Sep 2023 | major depressive disorder | Beijing Greatway Pharmaceutical Technology Co.,Ltd. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06964711 ↗ |
| Known as | GW117 ODT | “Drug: GW117 ODT” NCT06964711 ↗ |
| Known as | GW117 Orally Disintegrating Tablets | “GW117 Orally Disintegrating Tablets” NCT06964711 ↗ |
| Known as | N-(2-(6-chloro-7-deuteromethoxy-naphthalen-1-yl) ethyl) acetamide | “BACKGROUND: GW117 (N-(2-(6-chloro-7-deuteromethoxy-naphthalen-1-yl) ethyl) acetamide) is a dual-acting agent” PMID 41425080 ↗ Dec 2025 |
| Route | Oral | “GW117 Tablets 20mg orally once a day” NCT06796868 ↗ |